Journal of Antimicrobial Chemotherapy 2005,55(6):944–949.PubMed 117. Sahm D: In vitro activity of doripenem. Clin Infect Dis 2009,49(Suppl 1):S11–6.PubMed 118. Powell LL, Wilson SE: The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt) 2000,1(1):57–63. 119. Paterson

DL, Bonomo RA: Extended-Spectrum β-Lactamases: A Clinical Update. Clin Microbiol Rev 2005,18(4):657–686.PubMed 120. Paterson DL: Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect selleck chemicals llc Control 2006,34(5 Suppl 1):S20–8.PubMed 121. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 1990, 3:45–65. 122. Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, Lew D: A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection 2007,35(3):161–166.PubMed 123. Endimiani A, Perez F, Bonomo RA: Cefepime: A reappraisal in an era of increasing antimicrobial Selleck BAY 57-1293 resistance. Expert Rev Anti Infect Ther 2008,6(6):805–824.PubMed 124. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L: Efficacy and safety of cefepime: A systematic review and meta-analysis. Lancet Infect Dis 2007,7(5):338–348.PubMed 125.

Drago L, De Vecchi E: The safety of cefepime in the treatment of infection. Expert Opin Drug Saf 2008,7(4):377–387.PubMed 126. Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T: Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions. J Fam Pract 1996, 42:69–78.PubMed 127. Falagas ME, Matthaiou DK, Bliziotis IA: Systematic review: Fluoroquinolones for the treatment of intra-abdominal surgical infections. Aliment Pharmacol Ther 2007,25(2):123–131.PubMed 128. Coque TM, Baquero F, Canton R: Increasing prevalence

of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008.,20;13(47): 129. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H, AIDA Study Group: Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother 2009,21(2):170–180.PubMed 130. Stein GE: Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Ribonucleotide reductase Infect Dis 1996,23(suppl 1):S19–24.PubMed 131. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB: In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004,48(3):1012–1016.PubMed 132. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H: In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006,50(1):148–155.PubMed 133. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B: DRAGON Study Team. Int J Antimicrob Agents 2009,34(5):439–445.PubMed 134.